TY - JOUR
T1 - An analysis of FDA-approved drugs for infectious disease
T2 - HIV/AIDS drugs
AU - Kinch, Michael S.
AU - Patridge, Eric
N1 - Publisher Copyright:
© 2014 Elsevier Ltd. All rights reserved.
PY - 2014/10
Y1 - 2014/10
N2 - HIV/AIDS is one of the worst pandemics in history. According to the World Health Organization, 26 million people have died since 1981 - 1.6 million in 2012 alone. The dramatic rise in HIV/AIDS mobilized a swift and impressive coordination among governmental, academic and private sector organizations to identify the virus and develop new treatments. Herein, we assess the arsenal of 28 new molecular entities (NMEs) targeting HIV/AIDS. These data demonstrate that the first approval of zidovudine presaged an expansion of the antiviral repertoire over the following years. Whereas the rate of HIV/AIDS NMEs is rapidly declining, so is the number of organizations developing NMEs. We speculate that decisions to abandon further research reflect, in part, growing costs and time required for development.
AB - HIV/AIDS is one of the worst pandemics in history. According to the World Health Organization, 26 million people have died since 1981 - 1.6 million in 2012 alone. The dramatic rise in HIV/AIDS mobilized a swift and impressive coordination among governmental, academic and private sector organizations to identify the virus and develop new treatments. Herein, we assess the arsenal of 28 new molecular entities (NMEs) targeting HIV/AIDS. These data demonstrate that the first approval of zidovudine presaged an expansion of the antiviral repertoire over the following years. Whereas the rate of HIV/AIDS NMEs is rapidly declining, so is the number of organizations developing NMEs. We speculate that decisions to abandon further research reflect, in part, growing costs and time required for development.
UR - http://www.scopus.com/inward/record.url?scp=84908619738&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2014.05.012
DO - 10.1016/j.drudis.2014.05.012
M3 - Short survey
C2 - 24880109
AN - SCOPUS:84908619738
SN - 1359-6446
VL - 19
SP - 1510
EP - 1513
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 10
ER -